ArriVent Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Arrivent Biopharma

related news
Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Reuters

April 18 2026
Pfizer Ventures gets behind OTR Therapeutics’s $100M series A to boost R&D hub’s capability

Fierce Biotech

December 05 2025

Get In Touch

Contact Us